Shares drop as Biocompatibles' president resigns
This article was originally published in Clinica
Alistair Taylor, Biocompatibles' president and CEO, is to step down with immediate effect. Shares in the UK company subsequently fell 340p, valuing it at £94 million compared with the £1 billion peak it reached last year, according to the UK Times newspaper.
You may also be interested in...
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.
US regulators are proposing updates to a guidance document they finalized in February for devices used to clear arteries of plaque. The updated language specifically addresses software interoperability, pyrogenicity and certain performance-testing requirements.